MCRB news

Latest 1 stories · newest Nov 4, 2026

MCRB

Seres plans Q1 2027 FDA submission for SER-155 study to prevent immune checkpoint inhibitor-induced colitis

Seres Therapeutics reported Q3 2026 financial results and announced plans to submit a new study design for SER-155 to the FDA in Q1 2027, which aims to prevent immune checkpoint inhibitor-related enterocolitis and keep patients on life-saving cancer therapies. This news highlights the company's expa…

Earnings Nov 4, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same MCRB feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/MCRB/newsSTART FREE